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Abstract
Emerging evidence suggests that atrial fibrillation is associated with cognitive dysfunction 
independently of stroke, but the underlying mechanisms remain unclear. In this cross-sectional 
analysis from the Swiss-AF Study (NCT02105844), we investigated the association of serum 
neurofilament light protein, a neuronal injury biomarker, with (i) the CHA2DS2-VASc score 
(congestive heart failure, hypertension, age 65-74 or ≥ 75 years, diabetes mellitus, stroke or 
transient ischemic attack, vascular disease, sex), clinical and neuroimaging parameters and (ii) 
cognitive measures in atrial fibrillation patients.
We measured neurofilament light in serum using an ultrasensitive single-molecule array assay in 
a sample of 1,379 atrial fibrillation patients (mean age 72 years, 27% female). Ischemic infarcts, 
small vessel disease markers and normalized brain volume were assessed on brain MRI. Cognitive 
testing included the Montreal Cognitive Assessment, Trail Making Test, Semantic Verbal Fluency 
and Digit Symbol Substitution Test, which were summarized using principal component analysis. 
Results were analyzed using univariable and multivariable linear regression.
Neurofilament light was associated with the CHA2DS2-VASc score, with an average 19.2% (95% 
confidence interval [17.2%, 21.3%]) higher neurofilament per unit CHA2DS2-VASc increase. This 
association persisted after adjustment for age and MRI characteristics. In multivariable analyses, 
clinical parameters associated with neurofilament light were higher age (32.5% [27.2%, 38%] 
neurofilament increase per 10 years), diabetes mellitus, heart failure and peripheral artery disease 
(26.8% [16.8%, 37.6%], 15.7% [8.1%, 23.9%] and 19.5% [6.8%, 33.7%] higher neurofilament, 
respectively). Mean arterial pressure showed a curvilinear association with neurofilament, with 
evidence for both an inverse linear and a U-shaped association. MRI characteristics associated 
with neurofilament were white matter lesion volume and volume of large non-cortical or cortical 
infarcts (4.3% [1.8%, 6.8%] and 5.5% [2.5%, 8.7%] neurofilament increase per unit increase in 
log-volume of the respective lesion), as well as normalized brain volume (4.9% [1.7%, 8.1%] 
higher neurofilament per 100 cm3 smaller brain volume). Neurofilament light was inversely 
associated with all cognitive measures in univariable analyses. The effect sizes diminished after 
adjusting for clinical and MRI variables, but the association with the first principal component was 
still evident. 
Our results suggest that in atrial fibrillation patients, neuronal loss measured by serum 
neurofilament light is associated with age, diabetes mellitus, heart failure, blood pressure and 
vascular brain lesions, and inversely correlates with normalized brain volume and cognitive 
function.
https://mc.manuscriptcentral.com/braincom
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normalized brain volume; PC1, first principal component; PAD, peripheral artery disease; SD, 
standard deviation; SNCIs, small non-cortical infarcts; sNfL, serum neurofilament light; SVF, 
Semantic Verbal Fluency; SWI, susceptibility-weighted imaging; TIA, transient ischemic attack; 
TMT, Trail Making Test
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Introduction
Atrial fibrillation (AF) and dementia are highly prevalent in the elderly. AF is linked to dementia 
through ischemic stroke, but evidence has emerged that even in the absence of clinically manifest 
stroke, the risk of cognitive impairment and dementia is increased in patients with AF (Chen et al., 
2018; Madhavan et al., 2018; Kim et al., 2019). Several potential mechanisms have been 
postulated to explain this association, including silent cerebral infarcts, cerebral small vessel 
disease (through shared risk factors such as diabetes and hypertension) and cerebral hypoperfusion 
(Madhavan et al., 2018; Diener et al., 2019), but tangible evidence is lacking. With the progressive 
ageing of the population, AF and dementia are a continuously growing public health concern, and 
a deeper understanding of the pathophysiological pathways underlying their association will be 
crucial in developing strategies to preserve cognitive function in the elderly (Kuhne et al., 2019).
In a cross-sectional analysis from the Swiss Atrial Fibrillation (Swiss-AF) cohort study, we 
previously showed that cortical and large non-cortical infarcts were common in AF patients and 
were independently associated with a lower score on the Montreal Cognitive Assessment (MoCA), 
lending support to the hypothesis that cognitive dysfunction in AF might – at least in part – be 
mediated through covert cerebral embolic infarcts (Conen et al., 2019).
Here, we used serum neurofilament light protein (sNfL) to further explore the mechanisms that 
underly neuronal damage and cognitive dysfunction in AF. Neurofilaments are neuron-exclusive 
cytoskeletal proteins that are released in the extracellular space, cerebrospinal fluid and eventually 
peripheral blood following neuroaxonal damage. sNfL has emerged as a biomarker for neuronal 
injury in inflammatory, degenerative, traumatic and vascular neurological disorders (Khalil et al., 
2018), but has not yet been investigated as a marker of neurological disease in AF. In this analysis 
from the Swiss-AF cohort study we investigated the association of sNfL with (i) clinical 
parameters and neuroimaging characteristics and (ii) measures of cognitive function.
https://mc.manuscriptcentral.com/braincom
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Materials and methods
Study design, patient population and data collection
This was a cross-sectional analysis using baseline data from the ongoing prospective observational 
Swiss-AF cohort study (NCT02105844), that enrolled 2,415 AF patients between 2014 and 2017 
across 14 centers in Switzerland. The detailed methodology of Swiss-AF has been described 
previously (Conen et al., 2017; Conen et al., 2019). In short, Swiss-AF included patients with 
documented AF aged 65 years or older, with an additional 15% of patients aged between 45 and 
65 years. Patients with secondary forms of AF, those with a recent ischemic stroke, transient 
ischemic attack (TIA) or other acute illness (< 4 weeks) and those unable to provide informed 
consent (e.g., patients with dementia, psychosis or delirium) were excluded. Baseline information 
on sociodemographic parameters and comorbidities was collected based on patients’ history and/or 
medical chart review as applicable, using standardized case report forms. Upon inclusion, weight, 
height and the mean of 3 consecutive blood pressure measurements were obtained, and patients 
underwent blood sampling, brain MRI and cognitive testing. 
Baseline blood samples were collected following standard operating procedures (Conen et al., 
2017). After centrifugation, serum samples were aliquoted into cryotubes and stored at ˗80°C in a 
centralized biobank. sNfL concentrations were measured in duplicate using a previously described 
ultrasensitive single‐molecule array assay (Disanto et al., 2017). Inter-assay coefficients of 
variation were 10% for low (mean, 6.9 pg/mL), 12% for medium (mean, 19.6 pg/mL) and 5% for 
high (mean, 84.5 pg/mL) concentration quality control serum samples measured in duplicate in 
every run. The mean intra-assay coefficient of variation of duplicate determinations for 
concentration was 5%. Individuals performing sNfL measurements were blinded to clinical, MRI 
and cognitive patient data. 
Baseline brain MRI was acquired on a 1.5 or 3.0 Tesla scanner using a standardized protocol 
including a 3D T1-weighted magnetization-prepared rapid gradient echo (MPRAGE), a 2D axial 
fluid-attenuated inversion recovery (FLAIR), a 2D axial diffusion-weighted imaging (DWI) and a 
2D axial susceptibility-weighted imaging (SWI) or T2*-weighted sequence (Conen et al., 2017; 
Conen et al., 2019). All scans were analyzed centrally in a core lab (Medical Image Analysis 
Center AG, Basel, Switzerland) by expert raters blinded to clinical and cognitive patient data and 
sNfL measurements. We evaluated the following vascular brain lesions, which we defined 
adapting the STRIVE classification of small vessel disease (Wardlaw et al., 2013), as in previous 
https://mc.manuscriptcentral.com/braincom
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research (Conen et al., 2019): (i) Small non-cortical infarcts (SNCIs), defined as hyperintense 
lesions on FLAIR, ≤20mm in diameter on axial sections and not involving the cortex, consistent 
with ischemic infarction in the territory of a perforating arteriole and located in the white matter, 
internal or external capsule, deep brain nuclei, thalamus or brainstem. (ii) Large non-cortical 
infarcts were non-cortical infarcts with a diameter >20mm. Cortical infarcts were defined as 
FLAIR hyperintense lesions involving the cortex irrespective of their size and whether they also 
involved subcortical areas. Large non-cortical and cortical infarcts (LNCCIs) were grouped 
together in the analyses. All infarcts were characterized as recent (hyperintense) or chronic 
according to their appearance on DWI. (iii) FLAIR hyperintensities not meeting the 
aforementioned criteria for infarcts were identified as white matter lesions (WMLs). (iv) 
Microbleeds (MBs) were identified and counted as nodular, strongly hypointense lesions on either 
SWI or T2*-weighted sequences. T2-weighted volumes of SNCIs, LNCCIs and WMLs were 
segmented and quantified semi-automatically in mm3 using Amira (Mercury Computer Systems 
Inc., Chelmsford, Massachusetts). Lesions with a central FLAIR hypointense core were segmented 
in total without differentiating between hyperintense and hypointense lesion areas. The normalized 
brain volume (nBV) was estimated in cm3 on MPRAGE using SIENAX (Smith et al., 2002). 
Cognitive testing was performed by trained study personnel in a standardized manner and 
included:
(i) the MoCA, which assesses visuospatial and executive functions, confrontation naming, 
memory, attention, language and abstraction. Subjects could obtain a maximum of 30 points, 
with higher scores indicating better cognitive function. One point was added to the test score 
if the patient had ≤12 years of formal education (Nasreddine et al., 2005). 
(ii) the Trail Making Test (TMT), which assesses visual attention, processing speed and executive 
functioning. It consists of two parts (A and B), in which the subject was instructed to connect 
a set of 25 points, either circled numbers in ascending order (TMT-A) or circled numbers and 
letters in alternating numeric and alphabetic ascending order (TMT-B), as quickly as possible 
while maintaining accuracy. The number of correct connections and the time to test 
completion in seconds were measured, with a maximum allowed time of 180 and 300 seconds 
for TMT-A and TMT-B, respectively. The test metric was the number of correct answers per 
second, with higher scores indicating better cognitive function (Tombaugh, 2004). 
(iii) semantic verbal fluency (SVF), which assesses semantic memory and language production. 
Subjects were asked to name as many words as possible from the semantic category “animals” 
https://mc.manuscriptcentral.com/braincom
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within 60 seconds. The test metric was the number or correct responses, with higher scores 
indicating better cognitive function  (Morris et al., 1989). 
(iv) the Digit Symbol Substitution Test (DSST) of the Wechsler Adult Intelligence Scale, which 
assesses processing speed, visuomotor coordination and attention. The subject received a key 
grid of numbers and matching symbols and a test section with numbers and empty boxes. The 
test consisted of filling as many empty boxes as possible with the matching symbol from the 
key grid. The score was the number of correct number-symbol matches achieved within 120 
seconds, with higher scores indicating better cognitive function (Petermann, 2011). 
The detailed patient flowchart for the analyses of this study is given in Supplementary Figure 1. 
We included all Swiss-AF patients with quantifiable sNfL measurement and complete MRI data 
and excluded those with recent subclinical ischemic infarcts on DWI (which would expectedly 
raise sNfL concentrations disproportionately (Gattringer et al., 2017; De Marchis et al., 2018; 
Tiedt et al., 2018)). The Ethics Committee of Northwest and Central Switzerland approved Swiss-
AF including the present study (PB_2016-00793). Written informed consent was obtained from 
all study participants according to the Declaration of Helsinki. This study was conducted in 
accordance with the STROBE Statement for cross-sectional studies (von Elm et al., 2007).  
Statistical analyses
Analysis A: Association of the CHA2DS2-VASc score, clinical and MRI characteristics with 
sNfL 
To investigate the association of patients’ characteristics with sNfL, we fitted uni- and 
multivariable linear regression models with various sets of clinical and MRI variables as 
independent variables and the log-transformed sNfL concentration as dependent variable. 
Continuous independent variables were centered on their mean (or, in case of skewed data, median) 
values. We report the back-transformed model-based estimates, which represent multiplicative 
effects on the geometric mean of sNfL and are denoted by βmult (so that a one-unit increase in the 
independent variable is associated with an average βmult-fold change in sNfL), along with 95% 
confidence intervals (CI) and two-sided p-values. We interpret p-values as a continuous measure, 
with smaller values indicating stronger evidence for an association, but without specifying a 
threshold value. To compare between models, we used the Akaike’s information criterion (AIC), 
which estimates the relative quality of different models fitted to a given dataset, while penalizing 
models for larger number of independent variables. Lower AIC values indicate a better fit. 
Additionally, we provide the coefficient of determination (R2) of each model as a measure of the 
https://mc.manuscriptcentral.com/braincom
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proportion of the observed sNfL variance explained by the model. Since R2 tends to increase with 
the number of independent variables, we also provide the adjusted R2 (R2adj), which penalizes R2 
for larger numbers of variables. We fitted the following predefined models with log-sNfL as the 
dependent variable:
(i) the CHA2DS2-VASc score (congestive heart failure, hypertension, age 65-74 or ≥ 75 years, 
diabetes mellitus, stroke or TIA, vascular disease, sex) models: CHA2DS2-VASc is a validated 
clinical score predicting stroke risk in AF patients (Lip et al., 2010; Friberg et al., 2012). We 
opted to first investigate the association of sNfL with this risk score as a whole, independent 
of its individual components. Given the known association of sNfL with age (Khalil et al., 
2018), we fitted univariable models for the association of sNfL with age, with the CHA2DS2-
VASc score and with the CHA2DS2-VASc score after exclusion of its age component. 
Additionally, we fitted bivariable models for the age-adjusted association of sNfL with the 
CHA2DS2-VASc score and with the CHA2DS2-VASc score after exclusion of its age 
component. We selected the best fitting CHA2DS2-VASc score model based on AIC values, 
and proceeded to further adjust it for MRI markers of small vessel disease (SNCIs, MBs and 
WMLs) (Wardlaw et al., 2013) as well as for all MRI variables, as detailed below, in two 
additional multivariable models. 
(ii) the clinical model: We fitted a multivariable model for the association of sNfL with the 
following predefined clinical variables: age, sex, history of hypertension, diabetes mellitus, 
stroke or TIA, coronary heart disease, peripheral artery disease (PAD), heart failure, 
obstructive sleep apnea, AF type (paroxysmal, persistent, permanent), body mass index (BMI, 
calculated as weight in kg / height in m2), smoking status (active, past, non-smoker), alcohol 
consumption (number of standard drinks daily) and mean arterial pressure (MAP, calculated 
as 1/3 * systolic blood pressure + 2/3 * diastolic blood pressure (DeMers and Wachs, 2019)). 
We opted to use the MAP instead of including both systolic and diastolic blood pressure in 
the models due to collinearity between those variables. There was no evidence of collinearity 
upon visual inspection of scatter plots for any of the other continuous clinical variables, but 
there was evidence for a curvilinear association between sNfL and MAP, which we modelled 
by introducing an additional quadratic term (MAP2). We reduced the clinical model to a 
smaller set of variables via stepwise backward elimination based on AIC values. We imputed 
the few missing values in the clinical variables  with simple single imputation, using the mode 
(i.e., the most common category) for categorical variables and the mean (or, in case of skewed 
data, the median) for continuous variables (Table 1; one missing value in smoking status and 
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alcohol consumption, imputed with “past” and 0.6 standard drinks daily, respectively; six 
missing values in systolic and diastolic blood pressure, imputed with 134.7mmHg and 
78.4mmHg, respectively). 
(iii) the MRI model: We fitted a multivariable model for the age-adjusted association of sNfL with 
the following predefined MRI variables: nBV, SNCIs’ presence and log-transformed volume, 
LNCCIs’ presence and log-volume, MBs’ presence and count (truncated at 20 to reduce the 
influence of outliers) and WMLs’ log-volume.
(iv) the combined clinical and MRI model: We fitted a final combined model for the association 
of sNfL with the chosen clinical and all MRI variables from the models (ii) and (iii). 
Analysis B: Association of sNfL with measures of cognitive function
To investigate the association of sNfL with cognitive function we fitted linear regression models 
with the score of each of the cognitive tests (MoCA, TMT-A, TMT-B, SVF, DSST) as the 
dependent variable and the log-transformed sNfL concentration as independent variable. We report 
the model-based estimates, which represent additive effects on the mean of the test score and are 
denoted by β, along with the 95%CI and two-sided p-values. A one-unit increase in log-sNfL is 
associated with an average change in the test score of β units (or a 10% increase in sNfL is 
associated with a change of 0.095 * β units in the test score). For each cognitive test we fitted the 
following predefined models with test score as the dependent variable:
(i) univariable model (including only log-sNfL as independent variable)
(ii) age-adjusted model (including log-sNfL and age as independent variables)
(iii) clinical multivariable model, including log-sNfL, age, sex, education level (basic, middle, 
advanced), history of hypertension, diabetes mellitus, stroke or TIA, coronary heart disease, 
PAD, heart failure, obstructive sleep apnea, BMI, smoking status (active, past, non-smoker) 
and alcohol consumption (number of standard drinks daily) as independent variables. We 
imputed the few missing values in the clinical variables with simple single imputation, as 
described above. 
(iv) MRI multivariable model, including log-sNfL, age, nBV, SNCIs’ presence and log-volume, 
LNCCIs’ presence and log-volume, burden of MBs (categorized as 0, 1, 2 and ≥3) and WMLs’ 
log-volume as independent variables
(v) combined clinical and MRI multivariable model, including all aforementioned variables
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To summarize performance over all cognitive tests we used principal component analysis. The 
first principal component (PC1) explained 61.3% of the observed variance and the loading of each 
test on PC1 (representing the covariance between each test and PC1) was positive (MoCA: +0.40, 
TMT-A: +0.45, TMT-B: +0.50, SVF: +0.39, DSST: +0.49), thereby allowing for the use of PC1 
as a single, summary measure of cognitive function, with higher values indicating better cognitive 
performance. We additionally fitted all models (i) – (v) described above with PC1 as the dependent 
variable.  
As a sensitivity analysis, we repeated all models described under analyses A and B in the subset 
of patients without history of stroke or TIA. 
All analyses were performed with R version 3.5.2 (2018-12-20) (R Core Team, 2019).
Data availability
The Swiss-AF consent forms, as approved by the ethics committee, do not allow for the data to be 
made publicly available. Researchers may contact the authors for the potential submission of 
research proposals for future analyses or independent verification of our results. 
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Results
A total of 1,379 patients (mean [SD] age 72.3 [8.6] years, 27.1% female) with quantifiable sNfL 
measurement and complete MRI data were available for analysis A (Supplementary Figure 1). The 
median (IQR) sNfL concentration was 38.2 (26.6 – 56.4) pg/ml. The detailed demographic, clinical 
and MRI characteristics of all patients are presented in Table 1. 
Association of the CHA2DS2-VASc score with sNfL
The CHA2DS2-VASc score was associated with sNfL in univariable analysis, with an average 
19.2% increase in sNfL concentration per point increase in the CHA2DS2-VASc score (βmult = 
1.192, 95%CI [1.172, 1.213], p < 0.001; Figure 1). Age was also strongly associated with sNfL in 
univariable analysis (βmult = 1.489 per 10 years, 95%CI [1.440, 1.539], p < 0.001). The association 
between the CHA2DS2-VASc score and sNfL persisted after excluding the age component of the 
score, after adjusting for age and after both excluding the age component and adjusting for age. 
The model with the best fit was the one including the unmodified CHA2DS2-VASc score and 
adjusting for age, which was used in the rest of the analyses. The CHA2DS2-VASc score remained 
associated with sNfL after adjusting for MRI markers of small vessel disease and for all MRI 
variables combined (Supplementary Table 1). 
Association of clinical and MRI characteristics with sNfL
The detailed results of the clinical, MRI and combined models are given in Table 2. The clinical 
model fitted the data better and explained a larger proportion of the observed sNfL variance 
compared to the MRI model. The combined clinical and MRI model fitted the data best. Figure 2 
shows the effect size estimates for the association of all clinical and MRI variables with sNfL from 
the combined model: Parameters positively associated with sNfL were age (on average 32.5% 
higher sNfL per 10 years), history of diabetes mellitus (26.8% higher sNfL), PAD (19.5% higher 
sNfL) and heart failure (15.7% higher sNfL), as well as volume of LNCCIs and WMLs (5.5% and 
4.3% higher sNfL per unit increase in log-volume of the respective lesion). MAP showed a 
curvilinear association with sNfL, with an inverse linear and U-shaped component (Figure 3A). 
Parameters inversely associated with sNfL were BMI (7.3% lower sNfL per 5kg/m2 higher BMI), 
past smoker status (7% lower sNfL compared to non-smoker), alcohol consumption (1.9% lower 
sNfL per 1 standard drink daily) and nBV (4.9% lower sNfL per 100 cm3 larger nBV; Figure 3B).  
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Association of the sNfL with measures of cognitive function
Of the 1,379 patients with sNfL and MRI data, cognitive testing was incomplete in 16, leaving 
1,363 patients available for analysis B. The median (IQR) MoCA score was 26 (24 – 28) points, 
TMT-A and TMT-B scores were 0.53 (0.39 – 0.68) and 0.21 (0.14 – 0.28) correct connections per 
second, respectively, SVF score was 19 (15 – 23) correct responses and DSST score was 45 (36 – 
54) correct matches. The detailed results of all models for the association of sNfL with all cognitive 
measures are presented in Table 3. In univariable analyses, log-sNfL was strongly associated with 
all cognitive tests and the PC1, with higher sNfL concentrations indicating worse cognitive 
performance. The effect sizes generally diminished for all cognitive measures after adjusting for 
age, clinical variables and MRI characteristics. In the combined models adjusting for all 
aforementioned parameters, the association of log-sNfL with TMT-A, TMT-B and PC1 persisted. 
Figure 4 shows the model-based estimates for the association of sNfL with PC1. The scatter plot 
of the association of sNfL with PC1 is presented in Figure 5. 
Sensitivity analyses in patients without history of stroke or transient ischemic attack
After excluding those with history of stroke or TIA, 1,125 patients were available for sensitivity 
analysis A. Their median (IQR) sNfL concentration was 36.7 (25.5 – 53.2) pg/ml and their detailed 
demographic, clinical and MRI characteristics are presented in Table 1. Of those, 12 patients had 
incomplete cognitive testing, leaving 1,113 patients available for the sensitivity analysis B. Both 
sensitivity analyses in patients without history of stroke or TIA yielded consistent results with the 
main analysis (Supplementary Tables 2, 3 and 4). 
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Discussion
This cross-sectional study on the clinical, neuroimaging and cognitive correlates of sNfL in a large 
sample of AF patients showed the following key findings: (i) Higher CHA2DS2-VASc scores 
indicated increasing neuronal injury, independent of age and vascular brain lesions visible on MRI. 
(ii) Besides age, clinical factors associated with increased neuronal loss were diabetes mellitus, 
PAD, heart failure and lower MAP. (iii) MRI characteristics associated with higher sNfL were 
higher volume of WMLs and LNCCIs, as well as lower nBV. (iv) sNfL was associated with worse 
cognitive performance, an association which was largely but not exclusively explained by age, 
comorbidities and vascular brain lesions.
The CHA2DS2-VASc score, a validated clinical score predicting ischemic stroke risk in AF 
patients (Lip et al., 2010; Friberg et al., 2012), was associated with sNfL. This was independent 
of age, history of stroke and ischemic infarcts visible on MRI, as well as MRI markers of small 
vessel disease, and might therefore reflect ongoing ischemic brain injury in AF that evades 
detection on conventional MRI (Brundel et al., 2012). Higher CHA2DS2-VASc scores have 
previously also been associated with an increasing risk for dementia in stroke-free AF patients 
(Kim et al., 2019).
Our study in AF patients confirms the strong independent association of sNfL with age, which has 
been demonstrated across a wide variety of patient populations and healthy controls, probably 
reflecting neurodegenerative processes associated with normal ageing (Khalil et al., 2018; Khalil 
et al., 2020). Furthermore, we found that diabetes mellitus was associated with a sNfL increase by 
a similar magnitude as 10 years of age. In line with this, poor glycemic control was independently 
associated with sNfL in a previous study on sNfL among diabetics (Korley et al., 2019). The 
association of diabetes mellitus with sNfL was independent of small vessel disease markers and 
potentially embolic infarcts on MRI. It remains therefore unknown whether this association 
reflects increasing ischemic neuronal injury in the presence of diabetes mellitus due to 
microinfarcts that go undetected on conventional MRI (Brundel et al., 2012), some other non-
ischemic, diabetes-induced mechanism of neuronal damage in the central nervous system (Malone, 
2016) or the potential contribution of diabetic neuropathy in the peripheral nervous system 
(Mariotto et al., 2018). Peripheral artery disease was another independent determinant of sNfL, 
even after adjustment for vascular MRI brain lesions, which might again reflect increasing 
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ischemic brain injury that evades detection on conventional MRI (Brundel et al., 2012) in the 
presence of manifest atherosclerotic disease and is in line with cumulating evidence for the 
association of PAD with cognitive dysfunction independently of manifest cerebrovascular disease 
(Rafnsson et al., 2009). 
Interestingly, we found a curvilinear association of MAP with sNfL, with evidence for both an 
inverse linear and a U-shaped relationship, indicating increasing neuronal loss with lower MAP. 
This novel finding is in contrast to a previous smaller study in diabetics, which found a positive 
linear association of systolic blood pressure and no association of diastolic blood pressure with 
sNfL (Korley et al., 2019). Since MAP is a measure of the organ perfusion pressure (DeMers and 
Wachs, 2019), our finding suggests that neuronal damage in AF may be partly attributable to 
cerebral hypoperfusion. This was independent of history of heart failure, which was another 
independent determinant of sNfL, suggesting that hemodynamic changes in AF might adversely 
affect brain health above and beyond clinically manifest heart failure. Taken together, these 
findings refine and further support the hypoperfusion hypothesis for the association of AF with 
cognitive dysfunction (Madhavan et al., 2018; Diener et al., 2019), which has been proposed based 
on the known associations of cerebral hypoperfusion with dementia (Austin et al., 2011; Wolters 
et al., 2017; Iadecola et al., 2019), AF with cerebral hypoperfusion (Lavy et al., 1980; 
Gardarsdottir et al., 2017), and heart failure with cerebral hypoperfusion (Roy et al., 2017) and 
cognitive dysfunction (Vogels et al., 2007). Of note, recent studies in healthy individuals provide 
evidence for a U-shaped association of blood pressure with cognitive dysfunction (Lv et al., 2017) 
and for an inverse association of diastolic blood pressure with white matter disease (Fuhrmann et 
al., 2019) and cognitive decline (Levine et al., 2019). Putting our findings in this context, the 
curvilinear association of MAP with sNfL that we observed might not be specific to AF, but rather 
reflect a universal effect of blood pressure on brain health.  
Of all vascular MRI brain lesions, the volume of WMLs and chronic LNCCIs were the strongest 
independent determinants of sNfL, also after excluding patients with stroke history. This indicates 
that both small vessel disease and infarcts of potentially embolic origin, even clinically silent ones, 
contribute to neuronal injury in AF. Our finding is in line with previous research on the association 
of sNfL with the burden of small vessel disease (Gattringer et al., 2017; Duering et al., 2018; 
Uphaus et al., 2019) and the size of acute ischemic infarcts (Gattringer et al., 2017; Tiedt et al., 
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2018), and might suggest a greater severity of ongoing neurodegenerative processes secondary to 
ischemia (Tiedt et al., 2018) or persistent, active microischemic phenomena in the brain of AF 
patients with a higher burden of established, embolic or microangiopathic, ischemic MRI lesions. 
These findings demonstrate the potential of sNfL as a blood biomarker to select AF patients that 
would benefit from further MRI investigations to uncover potential subclinical vascular brain 
disease, considering that mass screening with MRI is not feasible and that sNfL in our cohort 
appeared to be sensitive to potential mechanisms of brain injury independent of structural changes 
visualized on MRI. Of note, the presence of MBs was only marginally associated with sNfL after 
adjustment for other brain lesions, an association that was further weakened in the combined 
model. Thus, MBs might represent a proxy marker of vascular brain disease and contribute little 
if any to neuronal injury per se, in line with previous observations (Akoudad et al., 2016; Conen 
et al., 2019).
Another major finding was the inverse association of normalized brain volume with sNfL, which 
was independent of age, history of stroke and vascular MRI brain lesions. This association, which 
has been described in neurological diseases including multiple sclerosis and dementias (Khalil et 
al., 2018), might reflect an underlying ongoing neurodegenerative process in AF. Indeed, AF has 
been previously associated with reduced brain volume independent of ischemic infarcts, with 
putative explanations being cerebral microinfarcts or hypoperfusion leading to brain atrophy 
(Stefansdottir et al., 2013; Piers et al., 2016).
Despite the in-depth neuroimaging patient characterization, the clinical model still explained a 
larger proportion of the sNfL variance than the MRI model. We can only speculate on the reasons 
for this: It is possible that microischemic, hemodynamic, degenerative or other, yet unknown 
processes lead to neuronal damage in AF while remaining undetected on conventional MRI. 
Finally, sNfL was inversely associated with cognitive performance in AF patients. This is in line 
with previous research on the association of sNfL with cognitive measures in patients with small 
vessel (Duering et al., 2018) and neurodegenerative diseases (Byrne et al., 2017; Mattsson et al., 
2017; Lin et al., 2018; van der Ende et al., 2019), and suggests that sNfL is a nondisease-specific 
marker of neuronal damage resulting in cognitive dysfunction. The association of sNfL with 
cognitive measures grew markedly weaker after adjusting for age and was further attenuated in the 
multivariable clinical and MRI models, indicating that a multitude of factors including ageing, 
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comorbidities and vascular brain lesions contribute to or mediate the association of neuronal 
damage with cognitive dysfunction in AF. Importantly, the association of sNfL with PC1, the 
summary cognitive measure, persisted after adjustment for all clinical and neuroimaging 
parameters, suggesting that additional unknown factors might contribute to this association. 
Among the separate cognitive measures, the strongest associations of sNfL were with TMT-A, 
TMT-B and – to a lesser extent – DSST, all measures of executive function, processing speed and 
attention. Preferential changes in these cognitive domains are known to reflect a vascular profile 
of cognitive dysfunction (O'Brien et al., 2003) and have been previously associated with AF 
(Nishtala et al., 2018). 
The strengths of our study include (i) its large sample size of AF patients with detailed clinical, 
neuroimaging and cognitive characterization, allowing for adjustment for several confounding 
factors and thus reducing the risk of spurious findings, (ii) the standardized manner of data 
acquisition, high rate of data completeness and blinded MRI assessment and sNfL measurement, 
reducing the risk of bias and (iii) its multicenter design, indicating a certain generalizability of our 
results, at least within the Caucasian population of central Europe. However, the following 
limitations must be acknowledged: (i) The study’s cross-sectional design, which allows only for 
assessment of association but not causality thereof. (ii) As Swiss-AF included exclusively AF 
patients, we did not have a comparison group of patients with other heart diseases or healthy 
controls. It is therefore unknown whether our results are specific to AF. (iii) A large number of 
Swiss-AF patients did not undergo brain MRI due to contraindications or claustrophobia and were 
thus ineligible for this study. It is therefore unknown whether our results are generalizable to AF 
patients unsuited for brain MRI. (iv) We were not able to adjust our analyses for diseases of the 
peripheral nervous system, which were not systematically collected in Swiss-AF but might 
contribute to sNfL (Khalil et al., 2018). (v) Neuroimaging was performed on 1.5 or 3.0 Tesla 
scanners, which might miss a relevant proportion of microinfarcts compared to higher resolution 
MRI (van Veluw et al., 2013). 
In conclusion, our study demonstrates the potential of sNfL as a tool to explore the mechanisms 
that underly cognitive dysfunction in AF. It seems likely that neuronal damage in AF results from 
a complex interplay between subclinical brain ischemia, altered hemodynamics and 
neurodegeneration. sNfL holds promise not only as an instrument to investigate the intricate 
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mechanisms underlying the heart-brain interactions, but also as a surrogate outcome parameter for 
brain health and cognitive function in cardiovascular research. In future Swiss-AF analyses we 
plan to investigate the prognostic significance of sNfL and other blood-based biomarkers of 
cardiovascular disease longitudinally with regards to the development of vascular brain lesions, 
brain atrophy and cognitive dysfunction over time.
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 Table 1 Patient demographic, clinical and MRI characteristics
All patients
(N = 1,379)
Patients without stroke/TIA
(N = 1,125) 
demographic and clinical data missing 
values rate
age, years, mean (SD) 72.3 (8.6) 0 % 71.7 (8.8)
sex, female, N (%) 374 (27.1) 0 % 297 (26.4)
AF-type, N (%)
paroxysmal
persistent
permanent
636 (46.1)
408 (29.6)
335 (24.3)
0 %
510 (45.3)
349 (31.0)
266 (23.6)
history of 
hypertension, N (%)
diabetes mellitus, N (%)
stroke or transient ischemic attack, N (%)
coronary heart disease, N (%)
peripheral artery disease, N (%)
heart failure, N (%)
obstructive sleep apnea, N (%)
930 (67.4)
190 (13.8)
 254 (18.4)
364 (26.4)
87 (6.3)
297 (21.5)
171 (12.4)
0 %
0 %
0 %
0 %
0 %
0 %
0 %
741 (65.9)
146 (13.0)
0 (0)
292 (26.0)
64 (5.7)
238 (21.2)
128 (11.4)
CHA2DS2-VASc score, median (IQR) 3 (2 – 4) 0 % 3 (2 – 4)
smoking status, N (%)
non-smoker
past smoker
active smoker
603 (43.8)
671 (48.7)
104 (7.5)
0.1 %
488 (43.4)
553 (49.2)
84 (7.5)
alcohol consumption, standard drinks / day, median (IQR) 0.6 (0.1 – 1.3) 0.1 % 0.6 (0.1 – 1.3)
education level, N (%)
basic
middle
advanced
157 (11.4)
679 (49.3)
541 (39.3)
0.1 %
128 (11.4)
555 (49.3)
442 (39.3)
body mass index, kg/m2, mean (SD) 27.5 (4.6) 0 % 27.6 (4.7)
systolic blood pressure, mmHg, mean (SD) 134.7 (18.7) 0.4 % 134.7 (18.6)
diastolic blood pressure, mmHg, mean (SD) 78.4 (11.9) 0.4 % 78.7 (11.9) 
mean arterial pressure, mmHg, mean (SD) 97.2 (12.6) 0.4 % 97.3 (12.7) 
oral anticoagulation, N (%) 1,240 (89.9) 0 % 1,004 (89.2)
MRI data
small non-cortical infarcts, N (%)
volume (if present), mm3, median (IQR)
293 (21.2)
60 (30 – 150)
0 %
200 (17.8)
56 (30 – 123)
large non-cortical and cortical infarcts, N (%)
volume (if present), mm3, median (IQR)
288 (20.9)
1,374 (252 – 7,454)
0 %
153 (13.6)
585 (162 – 4,002)
white matter lesions, N (%)
volume (if present), mm3, median (IQR)
1,368 (99.2)
3,662 (1,350 – 9,197)
0 %
1,116 (99.2)
3,335 (1,224 – 8,252)
microbleeds, N (%)
count (if present), median (IQR)
291 (21.1)
1 (1 – 2)
0 %
220 (19.6)
1 (1 – 2)
normalized brain volume, cm3, median (IQR) 1,411 (1,354 – 1,478) 0 % 1,417 (1,358 – 1,487)
SD, standard deviation; IQR, interquartile range
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Table 2: Association of patients’ clinical and MRI characteristics with sNfL
Clinical model*
AIC = 2079.05
R2 = 0.36, R2adj = 0.36
MRI model
AIC = 2148.29
R2 = 0.33, R2adj = 0.32
Combined model
AIC = 2040.56
R2 = 0.39, R2adj = 0.38
Variables
(N = 1,379)
βmult†
[95% CI] p-value
βmult†
[95% CI] p-value
βmult†
[95% CI] p-value
age (per 10 years) 1.411[1.365, 1.460] < 0.001
1.367
[1.312, 1.424] < 0.001
1.325 
[1.272, 1.380] < 0.001
BMI (per 5 kg/m2) 0.925[0.897, 0.955] < 0.001
0.927
[0.899, 0.957] < 0.001
MAP (per 10 mmHg) 0.961[0.939, 0.983] < 0.001
0.958
[0.937, 0.980] < 0.001
MAP2 (per 10 mmHg) 1.019[1.008, 1.031] 0.001
1.019
[1.007, 1.030] 0.002
history of hypertension 1.068[1.003, 1.138] 0.042
1.030
[0.967, 1.098] 0.351
history of diabetes mellitus 1.283[1.181, 1.394] < 0.001
1.268
[1.168, 1.376] < 0.001
history of stroke or TIA 1.137[1.059, 1.220] < 0.001
1.056
[0.978, 1.141] 0.166
history of peripheral artery disease 1.231[1.098, 1.380] < 0.001
1.195
[1.068, 1.337] 0.002
history of heart failure 1.181[1.102, 1.266] < 0.001
1.157
[1.081, 1.239] < 0.001
past smoker (ref: non-smoker) 0.925[0.873, 0.980] 0.008
0.930
[0.878, 0.984] 0.012
active smoker (ref: non-smoker) 0.950 [0.850, 1.060] 0.358
0.944
[0.847, 1.053] 0.301
alcohol consumption (per 1 standard 
drink daily)
0.984
[0.965, 1.002] 0.086
0.981
[0.963, 1.000] 0.045
presence of LNCCIs 1.100[1.025, 1.180] 0.008
1.049
[0.975, 1.128] 0.199
log-volume of LNCCIs 1.066[1.035, 1.099] < 0.001
1.055
[1.025, 1.087] < 0.001
presence of SNCIs 1.055[0.980, 1.136] 0.156
1.036
[0.965, 1.113] 0.330
log-volume of SNCIs 1.030[0.978, 1.085] 0.262
1.020
[0.970, 1.072] 0.442
presence of MBs 1.104[1.011, 1.207] 0.028
1.079
[0.991, 1.176] 0.079
count of MBs 1.017[0.987, 1.047] 0.266
1.013
[0.985, 1.042] 0.372
log-volume of WMLs 1.045[1.019, 1.071] < 0.001
1.043
[1.018, 1.068] <0.001
nBV (per 100cm3) 0.945[0.914, 0.978] 0.001
0.951
[0.919, 0.983] 0.003
* Sex, atrial fibrillation type, history of coronary heart disease and obstructive sleep apnea were eliminated from the final, reduced 
clinical model.
† The back-transformed model-based estimates βmult represent multiplicative effects on sNfL (e.g., βmult = 1.325 for age denotes an average 
1.325-fold increase in sNfL concentration, that is an average 32.5% sNfL increase, per 10 years older age.)
AIC, Akaike’s information criterion; BMI, body mass index; MAP, mean arterial pressure; TIA, transient ischemic attack; LNCCIs, 
large non-cortical or cortical infarcts; SNCIs, small non-cortical infarcts; MBs, microbleeds; WMLs, white matter lesions; nBV, 
normalized brain volume
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Table 3: Association of log-sNfL with measures of cognitive function 
univariable age-adjusted multivariable clinical model*
multivariable MRI 
model†
multivariable 
combined model‡Cognitive measures 
(N = 1,363) β
§
[95% CI] p-value
β§
[95% CI] p-value
β§ 
[95% CI] p-value
β§
[95% CI] p-value
β§
[95% CI] p-value
MoCA -0.93 [-1.17, -0.69] < 0.001
-0.37 
[-0.65, -0.10] 0.008
-0.23 
[-0.51, 0.05] 0.114
-0.22 
[-0.51, 0.06] 0.123
-0.15
[-0.44, 0.14] 0.307
TMT-A -0.11 [-0.13, -0.10] < 0.001
-0.04
[-0.06, -0.02] < 0.001
-0.04
[-0.06, -0.02] < 0.001
-0.03
[-0.04, -0.01] 0.009
-0.03
[-0.04, -0.01] 0.012
TMT-B -0.06 [-0.07, -0.05] < 0.001
-0.02
[-0.03, -0.01] < 0.001
-0.02
[-0.03, -0.01] < 0.001
-0.01
[-0.02, -0.00] 0.015
-0.01
[-0.02, -0.00] 0.023
SVF -1.56 [-2.00, -1.12] < 0.001
-0.46
[-0.97, 0.05] 0.076
-0.29
[-0.81, 0.24] 0.283
-0.14
[-0.67, 0.38] 0.587
-0.09
[-0.62, 0.45] 0.752
DSST -6.95 [-8.07, -5.83] < 0.001
-2.40
[-3.64, -1.16] < 0.001
-1.75
[-2.96, -0.54] 0.005
-0.98
[-2.23, 0.27] 0.124
-0.84
[-2.05, 0.37] 0.175
PC1 -0.98 [-1.11, -0.84] < 0.001
-0.34
[-0.49, -0.20] < 0.001
-0.27
[-0.41, -0.12] < 0.001
-0.18
[-0.33, -0.03] 0.016
-0.16
[-0.31, -0.01] 0.032
* adjusted for age, sex, education level, history of hypertension, diabetes mellitus, stroke or TIA, coronary heart disease, peripheral artery disease, 
heart failure, obstructive sleep apnea, BMI, smoking status, alcohol consumption 
adjusted for age, normalized brain volume, presence and volume of small non-cortical infarcts, presence and volume of large non-cortical or 
cortical infarcts, burden of MBs, volume of white matter lesions
 adjusted for age, sex, education level, history of hypertension, diabetes mellitus, stroke or TIA, coronary heart disease, peripheral artery disease, 
heart failure, obstructive sleep apnea, BMI, smoking status, alcohol consumption, normalized brain volume, presence and volume of small non-
cortical infarcts, presence and volume of large non-cortical or cortical infarcts, burden of MBs, volume of white matter lesions
The model-based estimates β represent additive effects on test score (e.g., β = -0.93 for the association of log-sNfL with MoCA denotes an average 
decrease of 0.93 points in the MoCA score per unit higher log-sNfL, or an average decrease of approx. 0.09 points in the MoCA score per 10% 
higher sNfL concentration)
MoCA, Montreal Cognitive Assessment; TMT, Trail Making Test; SVF, Semantic Verbal Fluency; DSST, Digit Symbol Substitution Test; PC1, 
first principal component 
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Figure legends
Figure 1: Boxplots of sNfL distribution stratified to CHA2DS2-VASc score
Figure 2: Multiplicative effect sizes of the association of clinical and MRI variables with sNfL 
from the combined model
Figure 3: Scatter plot of the association of (A) mean arterial pressure and (B) normalized 
brain volume with sNfL. The solid line represents the predicted values from the combined clinical 
and MRI model and the dashed lines represent the 95% pointwise confidence intervals.  
Figure 4: Model-based estimates for the association of log-sNfL with PC1
Figure 5: Scatter plot of the age-adjusted association of sNfL with PC1. The solid line 
represents the model-based predicted values and the dashed lines represent the pointwise 95% 
confidence intervals.
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Figure 1: Boxplots of sNfL distribution stratified to CHA2DS2-VASc score 
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Figure 2: Multiplicative effect sizes of the association of clinical and MRI variables with sNfL from the 
combined model 
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Figure 3: Scatter plot of the association of (A) mean arterial pressure and (B) normalized brain volume with 
sNfL. The solid line represents the predicted values from the combined clinical and MRI model and the 
dashed lines represent the 95% pointwise confidence intervals.   
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Figure 4: Model-based estimates for the association of log-sNfL with PC1 
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Figure 5: Scatter plot of the age-adjusted association of sNfL with PC1. The solid line represents the model-
based predicted values and the dashed lines represent the pointwise 95% confidence intervals. 
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Polymeris et al. 
Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates
Abbreviated Summary
In patients with atrial fibrillation we show that age, diabetes, heart failure, peripheral artery 
disease and subclinical ischemic brain lesions are associated with serum levels of 
neurofilament light chain, a biomarker of neuronal loss. Higher neurofilament levels were 
associated with smaller brain volume and worse cognitive performance.
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